VEGF/VPF: A modulator of microvascular function with potential roles in glomerular pathophysiology

Journal of Nephrology

Volumn 9, Issue 1, 1996, Pages 10-17

  Brenchley, Paul E ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

glomerular permeability; vascular endothelial growth factor; vascular permeability factor

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; VASCULOTROPIN;

CAPILLARY PERMEABILITY; GLOMERULUS; GLOMERULUS FILTRATION; HUMAN; REVIEW;

EID: 0029878103     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Tisher CC, Brenner BM. Structure and function of the glomerulus. In: Tisher CC, Brenner BM, eds. Renal pathology. v. 1 Philadelphia: Lippincott JB, 1989; 92-110.
2. Kanwar YS, Linker A, Farquhar MG. Anionic sites in the glomerular basement membrane. In vivo and in vitro localisation to the lamina rarae by cationic probes. J Cell Biol 1979; 81: 137-53.
3. Kanwar YS. Biology of disease: biophysiology of glomerular filtration and proteinuria. Lab Invest 1984; 18: 42-8.
4. Koshy V, Avasthi PS. The anionic sites at luminal surface of peritubular capillaries. Kidney Int 1987; 31: 52-8.
5. Daniels BS. The role of the glomerular epithelial cell in the maintenance of the glomerular filtration barrier. Am J Nephrol 1993; 13 (5): 318-23.
6. Rodewald R, Karnovsky MJ. Porous substructure of the glomerular slit diaphragm in the rat and mouse. J Cell Biol 1974; 60 (2): 423-33.
7. Salant DJ, Quigg RJ, Cybulsky AV. Heymann nephritis: mechanisms of renal injury. Kidney Int 1989; 35 (4): 976-84.
8. Kanwar YS, Rosenzweig LJ. Altered glomerular permeability as a result of focal detachment of the visceral epithelium. Kidney Int 1982; 21 (4): 565-74.
9. Daniels BS, Hauser EB, Deen WM, Hostetter TH. Glomerular basement membrane: in vitro studies of water and protein permeability. Am J Physiol 1992; 262 (6 Pt 2): F919-26.
10. Daniels BS. Increased albumin permeability in vitro following alterations of glomerular charge is mediated by the cells of the filtration barrier. Journal of Laboratory and Clinical Medicine 1994; 124 (2): 224-30.
11. Clementi F, Palade GE. Intestinal capillaries. I. Permeability to peroxidase and ferritin. J Cell Biol 1969; 41 (1): 33-58.
12. Granger DN, Granger JP, Brace RA, Parker RE, Taylor AE. Analysis of the permeability characteristics of cat intestinal capillaries. Circ Res 1979; 44 (3): 335-44.
13. Bearer EL, Orci L. Endothelial fenestral diaphragms: a quick-freeze, deep-etch study. J Cell Biol 1985; 100 (2): 418-28.
14. Bulger RE, Eknoyan G, Purcell DJ, Dobyan DC. Endothelial characteristics of glomerular capillaries in normal, mercuric chloride-induced, and gentamicin-induced acute renal failure in the rat. J Clin Invest 1983; 72: 128-41.
15. Vasmant D, Maurice M, Feldmann G. Cytoskeleton ultrastructure of podocytes and glomerular endothelial cells in man and in the rat. Anat Rec 1984; 210: 17-24.
16. Brown LF, Berse B, Tognazzi K, et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992; 42 (6): 1457-61.
17. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13 (1): 18-32.
18. Senger DR, Galli SS, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5.
19. Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterisation of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 1989; 86: 7311-5.
20. Connolly DT, Olander JV, Heuvelman D, et al. Human vascular permeability factor. J Biol Chem 1989; 264: 20017-.
21. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5 (2): 1806-14.
22. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267 (36): 26031-7.
23. Park JE, Keller GA, Ferrara N. Vascular endothelial growth factor (Vegf) isoforms - Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound Vegf. Molecular Biology of the Cell 1993; 4 (12): 1317-26.
24. Charnock-Jones DS, Sharkey AM, Rajput-Williams J, et al. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol Reprod 1993; 48 (5): 1120-8.
25. Potgens AJG, Lubsen NH, Vanaltena MC, et al. Covalent dimerization of vascular permeability factor vascular endothelial growth factor is essential for its biological activity - Evidence from Cys to Ser mutations. Journal of Biological Chemistry 1994; 269 (52): 32879-85.
26. Peretz D, Gitay-Goren H, Safran M, Kimmel N, Gospodarowicz D, Neufeld G. Glycosylation of vascular endothelial growth factor is not required for its mitogenic activity. Biochem Biophys Res Commun 1992; 182 (3): 1340-7.
27. Conn G, Bayne ML, Soderman DD, et al. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 1990; 87 (7): 2628-32.
28. Disalvo J, Bayne ML, Conn G, et al. Purification and characterization of a naturally occurring vascular endothelial growth factor placenta growth factor heterodimer. Journal of Biological Chemistry 1995; 270 (13): 7717-23.
29. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and N-terminal amino acid sequence of guinea pig tumour-secreted vascular permeability factor. Cancer Res 1990; 50: 1774-8.
30. Iijima K, Yoshikawa N, Connolly D, Nakamura H. Expression of vascular permeability factor by mesangial cells. Journal of the American Society of Nephrology 1992; 3: 514a.
31. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Research 1995; 55 (2): 360-8.
32. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. Journal of Cell Science 1995 Jun; 108: 2369-79.
33. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology 1995; 146 (5): 1029-39.
34. Kohn S, Nagy JA, Dvorak HF, Dvorak AM. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab Invest 1992; 67 (5): 596-607.
35. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3 (2): 211-20.
36. Ferrara N, Winer J, Burton T. Aortic smooth muscle cells express and secrete vascular endothelial growth factor. Growth Factors 1991; 5 (2): 141-8.
37. Iijima K, Yoshikawa N, Connolly DT, Nakamura H. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int 1993; 44 (5): 959-66.
38. Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Research 1995; 55 (18): 4140-5.
39. Myers CR, Webb NJA, Green L, Brenchley PEC. Human peripheral blood neutrophils produce vascular permeability factor. Int Journal of Experimental Pathology 1996 (in press).
40. Shifren JL, Doldi N, Ferrara N, Mesiano S, Jaffe RB. In the human fetus, vascular endothelial growth factor is expressed in epithelial cells and myocytes, but not vascular endothelium: implications for mode of action. Joutnal of Clinical Endocrinology and Metabolism 1994; 79 (1): 316-22.
41. Uchida K, Uchida S, Nitta K, Yumura W, Marumo F, Nihei H. Glomerular endothelial cells in culture express and secrete vascular endothelial growth factor. American Journal of Physiology 1994; 266 (1): F81-8.
42. Jakeman LB, Winer J, Bennett GL, Altar CA, Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 1992; 89 (1): 244-53.
43. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255 (5047): 989-91.
44. Galland F, Karamysheva A, Pebusque MJ, et al. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene 1993; 8: 1233-40.
45. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187 (3): 1579-86.
46. Pajusola K, Aprelikova O, Pelicci G, Weich H, Claessonwelsh L, Alitalo K. Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene 1994; 9 (12): 3545-55.
47. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proceedings of the National Academy of Sciences of the United States of America 1995; 92 (8): 3566-70.
48. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Fit-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376 (6535); 66-70.
49. Kaipainen A, Korhonen J, Pajusola K, et al. The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. Journal of Experimental Medicine 1993; 178 (6): 2077-88.
50. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity and promotes monocyte migration. J Exp Med 1990; 172: 1535-45.
51. Shen H, Claus M, Ryan J, et al. Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood (United States) 1993; 81 (10): 2767-73.
52. Kim KJ, Li B, Houck K, Winer J, Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 7 (1): 53-64.
53. Sioussat TM, Dvorak HF, Brock TA, Senger DR. Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. Arch Biochem Biophys 1993; 301 (1): 15-20.
54. Tessler S, Rockwell P, Hicklin D, et al. Heparin modulates the interaction of Vegf(165) with soluble and cell associated Flk-1 receptors. Journal of Biological Chemistry 1994; 269 (17): 12456-61.
55. Cohen T, Gitaygoren H, Sharon R, et al. VEGF(121), a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VTGF receptors of human melanoma cells. Journal of Biological Chemistry 1995; 270 (19): 11322-6.
56. Waltenberger J, Claessonwelsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. Journal of Biological Chemistry 1994; 269 (43): 26988-95.
57. Enomoto T, Okamoto T, Sato JD. Vascular endothelial growth factor induces the disorganization of actin stress fibers accompanied by protein tyrosine phosphorylation and morphological change in Balb/c3T3 cells. Biochemical and Biophysical Research Communications 1994; 202 (3): 1716-23.
58. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995; 10 (1): 135-47.
59. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-beta receptor. Nature 1994; 370 (6488): 341-7.
60. Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. American Journal of Pathology 1993; 143 (5): 1255-62.
61. Morii K, Tanaka R, Washiyama K, Kumanishi T, Kuwano R. Expression of vascular endothelial growth factor in capillary hemangioblastoma. Biochem Biophys Res Common (United States) 1993; 194 (2): 749-55.
62. Dvorak HF, Sioussat TM, Brown LF, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991; 174 (5): 1275-8.
63. Hlatky L, Tsionou C, Hahnfeldt P, Coleman CN. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Research 1994; 54 (23): 6083-6.
64. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359 (6398): 843-5.
65. Brogi E, Wu TG, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994; 90 (2): 649-52.
66. Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. Journal of Biological Chemistry 1994; 269 (6): 4355-9.
67. Minchenko A, Salceda S, Bauer T, Caro J. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cellular & Molecular Biology Research 1994; 40 (1): 35-9.
68. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995; 375 (6532): 577-81.
69. Hashimoto E, Ogita T, Nakaoka T, Matsuoka R, Takao A, Kira Y. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. American Journal of Physiology - Heart and circulatory physiology 1994; 36 (5): H1948-54.
70. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovascular Research 1994; 28 (8): 1176-9.
71. Peer J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Laboratory Investigation 1995; 72 (6): 638-45.
72. Li J, Perrella MA, Tsai JC, et al. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. Journal of Biological Chemistry 1995; 270 (1): 308-12.
73. Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: synergistic interaction with hypoxia. Circulation 1995; 92 (1): 11-4.
74. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. Journal of Biological Chemistry 1994; 269 (9): 6271-4.
75. Pepper MS, Vassalli JD, Orci L, Montesano R. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cells Res 1993; 204 (2): 356-63).
76. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995; 25 (5): 913-7.
77. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet derived growth factor A chain and c-myc gene expressions by angiotensin II in cultured rat smooth muscle cells. J Clin Invest 1989; 83: 1419-24.
78. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell (United States) 1993; 4 (1): 121-33.
79. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. Journal of Experimental Medicine 1994; 180 (3): 1141-6.
80. Harada S, Nagy JA, Sullivan KA, et al. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest 1994; 93 (6): 2490-6.
81. Pepper MS, Ferrara N, Orci L, Montesano R. Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro. Journal of Cell Science 1995 Jan; 108 (Part 1): 73-83.
82. Hu DE, Fan TPD. Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A. British Journal of Pharmacology 1995; 114 (2): 262-8.
83. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia - Modulation of gene expression by nitric oxide. Journal of Clinical Investigation 1995; 95 (4): 1798-807.
84. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993; 92: 99-104.
85. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (England) 1993; 362 (6423): 841-4.
86. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proceedings of the National Academy of Sciences of the United States of America 1993; 90 (22): 10705-9.
87. Kendall RL, Wang G, Disalvo J, Thomas KA. Specificity of vascular endothelial cell growth factor receptor ligand binding domains. Biochemical and Biophysical Research Communications 1994; 201 (1): 326-30.
88. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor - A cytokine modulating endothelial function in rheumatoid arthritis. Journal of Immunology 1994; 152 (8): 4149-56.
89. Fava RA, Olsen NJ, Spencer-Green G, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994; 180 (1): 341-6.
90. Nagashima M, Yoshino S, Ishiwata T, Asano G. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. Journal of Rheumatology 1995; 22 (9): 1624-30.
91. Ferrara N. Vascular endothelial growth factor - The trigger for neovascularization in the eye. Laboratory Investigation 1995; 72 (6): 615-8.
92. Simon M, Grone HJ, Johren O, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. American Journal of Physiology - Renal Fluid and Electrolyte Physiology 1995; 37 (2): F240-50.
93. Asscher AW, Anson SG. A vascular permeability factor of renal origin. Nature 1963; 198: 1097-9.
94. Shaloub RJ. Pathogenesis of lipoid nephrosis: a disorder of T cell function. Lancet 1974; 2: 556-60.
95. Mallick NP, Williams RJ, McFarlane H, Orr WM, Taylor G, Williams G. Cell-mediated immunity in nephrotic syndrome. Lancet 1972; 1 (749): 507-9.
96. Lagrue G, Xheneumont S, Branallec A, Hirbec G, Weil BA. Vascular permeability factor elaborated from lymphocytes. Demonstration in patients with nephrotic syndrome. Biomedicine 1975; 23: 37-40.
97. Boulton-Jones JM, Tulloch I, Dore B, McLay A. Changes in the glomerular capillary wall induced by lymphocyte products and serum of nephrotic patients. Clinical Nephrology 1983; 20: 72-7.
98. Bakker W, Vos TWM, Hoedemaeker PJ. Corticosteroid-sensitive peripheral blood cells are able to affect glomerular polyanion (GPA) in vitro. Immunology Letters 1982; 5: 11-4.
99. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991; 40: 453-60.
100. Bakker W, van Luijk WHJ. Do circulating factors play a role in the pathogenesis of minimal change nephrotic syndrome? Paediatric Nephrology 1989; 3: 341-9.
101. Ritz E. Pathogenesis of idiopathic nephrotic syndrome. New England Journal of Medicine 1994; 330: 61-2.
102. ISKD Report. International study of kidney disease in children: Nephrotic syndrome in children. Kidney Int (United States29 13: 159-65.
103. Koskimies O. Archives of disease in childhood. 1982; 57: 544-8.
104. Glassock RJ, Cohen AH, Adler S, Ward H. Primary glomerular diseases. In: Brenner BM, Rector FC, eds. The Kidney. 3rd edn ed. Philadelphia: Saunders, 1986; 929-1013.
105. Lagrue G, Laurent J. Nouvelle Press Medicale 1984; 11: 1465-6.
106. Silva FG, Hogg RJ. Minimal change nephrotic syndrome. In: Tisher CC, Brenner BM, eds. Renal pathology. Philadelphia: Lippencott JB, 1989; 265-339.
107. Webb NJA, Lewis MA, Postlethwaite RJ, Brenchley PEC. Increased expression of vascular permeability factor (VPF) during relapse of childhood steroid sensitive nephrotic syndrome. Nephrol Dial Transplant 1995 (in press).
108. Folkman J. Angiotensin in cancer, vascular, rheumatoid and other disease. Nature Medicine 1995; 1: 27-31.